New pill aims to stop aggressive Lymphoma's return
NCT ID NCT07300514
Summary
This study is testing if a daily pill called golidocitinib can help keep an aggressive type of blood cancer (peripheral T-cell lymphoma) from coming back after initial chemotherapy. It will involve about 136 adults whose cancer has shrunk or disappeared after first treatment but who are not getting a stem cell transplant. Participants will take either the real pill or a placebo (sugar pill) for up to two years to see which group stays cancer-free longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.